• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Rani E. George, MD, PhD


  • Jamin Y, Glass L, Hallsworth A, George R, Koh DM, Pearson AD, Chesler L, Robinson SP.
    Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma.
    PLoS ONE. 2014;9(3):e92886.
  • Pei D, Luther W, Wang W, Paw BH, Stewart RA, George RE.
    Distinct neuroblastoma-associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models.
    PLoS Genet. 2013 Jun;9(6):e1003533.
  • Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson AD, Eccles SA, Chesler L, George RE.
    The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
    Cancer Cell. 2012 Jul 10;22(1):117-30.
  • Garcia I, Mayol G, Rodriguez E, Sunol M, Gershon TR, Rios J, Cheung NK, Kieran MW, George RE, Perez-Atayde AR, Casala C, Galvan P, de Torres C, Mora J, Lavarino C.
    Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma.
    Mol Cancer. 2010 Oct 15;9(1):277.
  • George RE, Lahti JM, Adamson PC, Zhu K, Finkelstein D, Ingle AM, Reid JM, Krailo M, Neuberg D, Blaney SM, Diller L.
    Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.
    Pediatr Blood Cancer. 2010 Oct;55(4):629-38.
  • George RE, Diller L, Bernstein ML.
    Pharmacotherapy of neuroblastoma.
    Expert Opin Pharmacother. 2010 Jun;11(9):1467-78. Review.
  • Volchenboum SL,Li C,Li S,Attiyeh EF,Reynolds CP,Maris JM,Look AT,George RE.
    Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis.
    Cancer Res. 2009 May 15;69(10):4143-9.
  • George RE,Sanda T,Hanna M,Frohling S,Luther W 2nd,Zhang J,Ahn Y,Zhou W,London WB,McGrady P,Xue L,Zozulya S,Gregor VE,Webb TR,Gray NS,Gilliland DG,Diller L,Greulich H,Morris SW,Meyerson M,Look AT.
    Activating mutations in ALK provide a therapeutic target in neuroblastoma.
    Nature. 2008 Oct 16;455(7215):975-8.
  • George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JM.
    Genome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays.
    PLoS ONE. 2007;2:e255.
  • George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA, Diller L.
    High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
    J Clin Oncol. 2006 Jun 20;24(18):2891-6.
  • Stewart RA, Arduini BL, Berghmans S, George RE, Kanki JP, Henion PD, Look AT.
    Zebrafish foxd3 is selectively required for neural crest specification, migration and survival.
    Dev Biol. 2006 Apr 1;292(1):174-88.
  • George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT.
    Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    J Clin Oncol. 2005 Sep 20;23(27):6466-73.